Melnick–Fraser Syndrome

Melnick–Fraser syndrome is a rare, inherited condition that affects the neck (branchial arches), the ears (outer, middle, and inner parts), and the kidneys and urinary tract. “Branchio” refers to the branchial arches in the embryo that form parts of the neck and ear. “Oto” means ear. “Renal” means kidney. Children and adults with this syndrome may have small openings or cysts in the neck (called branchial cleft pits, sinuses, or cysts), ear differences and hearing loss, and kidney changes that range from mild to severe. The condition usually follows an autosomal dominant pattern, which means one changed copy of the gene is enough to cause it, and it often runs in families. Doctors also use the term branchio-oto-renal spectrum disorder (BORSD) to show that the features can vary widely from person to person—even within the same family. NCBI+1

Melnick–Fraser syndrome is a genetic condition that affects the neck (branchial area), the ears (outer, middle, inner), and the kidneys or urinary system. People may have small pits or cysts on the side of the neck, tiny holes or tags in front of the ear, hearing loss (conductive, sensorineural, or mixed), and kidney problems that range from mild changes to kidney failure. The condition usually runs in families in an autosomal dominant way, which means a child can get it when one parent carries the changed gene. The most common gene is EYA1; SIX1 and SIX5 can also cause it. Signs vary a lot, even in the same family. Some people have ear and neck findings but no kidney involvement (this is often called branchio-otic syndrome). Early hearing and kidney checks are important to protect language, growth, and long-term health. rarediseases.org+3NCBI+3rarediseases.info.nih.gov+3

Other Names

People and articles may use different names for the same condition. You can see these in clinic notes or genetics reports:

• Melnick–Fraser syndrome (the classic eponym). europepmc.org

• Branchio-oto-renal syndrome (BOR). rarediseases.info.nih.gov

• Branchio-oto-renal spectrum disorder (BORSD) (used to emphasize the range of findings). NCBI

• Branchio-otic (BO) syndrome when kidney changes are absent but branchial/ear signs are present. NCBI

• Branchio-oto-renal syndrome type 1/2/3 (historical subtype names linked to gene loci). Nature

Types

Doctors often describe “types” by what body systems are involved or which gene is changed. In day-to-day care, the “types” mainly help with counseling and testing.

1. Branchio-oto-renal (BOR) form
   This form includes neck pits/cysts, ear malformations with hearing loss, and kidney involvement such as small kidneys, kidney scarring, poor drainage, or vesicoureteral reflux (urine flowing backward). Severity ranges from mild kidney changes to serious kidney failure in a minority. NCBI

2. Branchio-otic (BO) form
   This form has branchial and ear findings with no kidney problems. Hearing loss can be conductive, sensorineural, or mixed. BO and BOR are part of one spectrum. NCBI

3. Gene-defined types

• EYA1-related BOR/BORSD (most common; many variants are loss-of-function): typically shows variable ears/neck/kidney findings in the same family. NCBI+1

• SIX1-related BOR/BO (less common; often missense variants affecting protein interaction/DNA binding). NCBI

• SIX5-related cases have been reported but are less certain; some experts now question whether SIX5 alone causes typical BOR. Your genetics team will interpret any SIX5 finding in the context of the whole picture. Dayton Children’s Hospital

---

Causes

Although people ask for “causes,” this syndrome is genetic. The items below explain how gene changes lead to the condition and why families may see different patterns. These points reflect current knowledge about EYA1 and SIX1 and the branchial–ear–kidney development pathway. NCBI+1

1. Pathway disruption during early development
   EYA1 and SIX1 work together to turn other genes on and off while the embryo forms the neck arches, ears, and kidneys. When the pathway is disrupted, those structures may not form normally. MedlinePlus

2. EYA1 haploinsufficiency
   Many EYA1 variants reduce the amount of working protein (one working copy is not enough). This “insufficient dose” causes the features of BOR. NCBI

3. SIX1 missense variants
   Some SIX1 changes alter a single amino acid in the protein, disrupting its binding to DNA or partner proteins and leading to ear and kidney developmental errors. NCBI

4. Copy-number variants (deletions/duplications)
   Larger pieces of DNA containing EYA1 (or its regulatory regions) can be deleted or duplicated, producing BOR features. Modern testing detects these. NCBI

5. Regulatory-region variants
   Changes not in the coding gene but in control regions around EYA1 can silence it at key times in development. NCBI

6. Splice-site variants
   Variants that affect how RNA is spliced can create truncated or nonfunctional EYA1 protein. NCBI

7. Nonsense-mediated decay
   Some variants create a premature stop signal; the cell destroys the faulty message, leaving too little EYA1. NCBI

8. Dominant inheritance
   One altered copy is enough to cause the condition. Each child of an affected person has a 50% chance to inherit it. rarediseases.info.nih.gov

9. De novo variants
   A change can appear for the first time in a child (neither parent has it), so family history may be negative. NCBI

10. Variable expressivity
    The same variant can cause mild findings in one person and severe findings in another, even in the same family. NCBI

11. Incomplete penetrance
    Some people who carry the variant may have very subtle or no obvious signs, which can hide the family pattern. NCBI

12. Gene–gene interactions
    EYA1 interacts with SIX proteins; a change in one can magnify the effect of a change in the other. MedlinePlus

13. Embryonic branchial arch malpatterning
    Disrupted signaling leads to persistent clefts or cysts in the neck. NCBI

14. Abnormal otic placode development
    Early ear structures may form in the wrong shape/position, leading to ear canal, ossicle, or cochlear differences and hearing loss. NCBI

15. Metanephric kidney development errors
    Kidneys may be small, under-formed, malpositioned, or scarred due to abnormal formation and drainage. Iowa Head and Neck Protocols

16. Urinary tract obstruction or reflux predisposition
    Valve and ureter development may be altered, increasing risk of vesicoureteral reflux or obstruction. NCBI

17. Temporal bone malformations
    Inner-ear bones and canals may be malformed, adding conductive or mixed hearing loss. PubMed

18. Middle ear ventilation problems
    Eustachian tube shape can lead to recurrent fluid and infections, worsening hearing. rarediseases.org

19. Rare mosaicism
    In some families, a parent may carry the variant in some cells but show few signs; children can still inherit it in all cells. (Recognized in many autosomal dominant conditions, and considered in BOR work-ups.) NCBI

20. Unidentified gene(s) in a minority
    A small number of families have the clinical picture but no change in EYA1 or SIX1; research suggests additional loci exist. Nature

---

Symptoms

Not everyone has every symptom. The pattern and severity differ widely, even in one family. NCBI

1. Preauricular pits or tags
   Small dimples or skin tags in front of the ear. They are harmless but can get infected or drain. They are a common clue for this syndrome. rarediseases.org

2. Branchial cleft pits, sinuses, or cysts in the neck
   Tiny openings, tracts, or cysts along the side of the neck. They may swell or drain fluid, especially with infections. Surgery sometimes helps. NCBI

3. Conductive hearing loss
   Problems with the ear canal, eardrum, or middle-ear bones reduce sound transmission. Hearing aids or surgery can help some people. PubMed

4. Sensorineural hearing loss
   Inner-ear or nerve changes reduce the ear’s ability to detect sound. It may be present at birth or appear later and can be stable or progressive. NCBI

5. Mixed hearing loss
   Both conductive and sensorineural components occur at the same time. PubMed

6. Auricular shape differences
   Ears may be low-set, “lop-ear,” cupped, or differently shaped. These changes may accompany hearing issues. PubMed

7. Recurrent ear infections or fluid (otitis media with effusion)
   Eustachian tube function can be altered, leading to frequent ear fluid and temporary hearing dips. rarediseases.org

8. Kidney hypoplasia or dysplasia
   One or both kidneys may be small or formed with abnormal tissue. This can reduce kidney function over time in some people. NCBI

9. Vesicoureteral reflux (VUR)
   Urine flows backward from the bladder toward the kidney, raising the risk of infections and scarring. NCBI

10. Hydronephrosis or poor drainage
    Urine backs up and stretches the kidney. Ultrasound often detects this early. NCBI

11. Urinary tract infections (UTIs)
    Children and adults may have UTIs due to reflux or other structural changes. Repeated UTIs can harm kidneys. NCBI

12. High blood pressure due to kidney disease
    If kidney function falls or scarring develops, blood pressure can rise. Monitoring is important. ajkd.org

13. Reduced kidney function
    Some individuals develop chronic kidney disease; others keep normal function lifelong. Early checks and follow-up help protect kidneys. NCBI

14. Facial or neck asymmetry
    Subtle differences in facial or neck structure may appear because of branchial arch development changes. NCBI

15. Balance issues or tinnitus (ringing)
    Inner-ear changes can cause dizziness or ringing. Audiology and ENT teams can guide care. NCBI

---

Diagnostic Tests

Diagnosis is based on clinical signs and genetic testing. Doctors also check hearing and kidney health at baseline and over time. NCBI

A) Physical Examination

1. General dysmorphology and growth exam
   A clinician looks for preauricular pits/tags, branchial pits/cysts, ear shape, neck masses, and facial asymmetry. This first step guides all other testing. NCBI

2. Focused neck exam
   Gentle pressure and light may reveal a small pit or tract along the anterior border of the sternocleidomastoid muscle, suggesting a branchial cleft remnant. NCBI

3. Ear inspection and otoscopy
   Exam of the auricle, canal, and eardrum for shape, canal stenosis, retractions, or fluid levels. This helps separate conductive from sensorineural elements. PubMed

4. Abdominal/palpation exam
   In some children, a solitary or enlarged kidney may be palpable, and flank tenderness may hint at infection or obstruction, prompting imaging. ajkd.org

5. Blood pressure measurement
   Hypertension can signal kidney involvement and needs ongoing tracking. ajkd.org

B) Manual/Bedside Tests

6. Tuning fork tests (Rinne and Weber)
   Simple bedside checks help screen for conductive vs sensorineural hearing loss before formal audiology testing. PubMed

7. Ear canal patency check
   Gentle manual assessment ensures the canal is open enough for sound conduction and for safe hearing-aid fitting if needed. PubMed

8. Neck transillumination and gentle compression
   A soft, cystic neck mass that transilluminates or drains suggests a branchial cyst or sinus and supports the diagnosis. NCBI

9. Simple urinary dipstick
   A bedside dipstick can quickly screen for protein or blood in urine, hinting at kidney involvement. Lab confirmation follows. NCBI

C) Laboratory & Pathological Tests

10. Urinalysis (microscopy)
    Looks for red cells, white cells, protein, or bacteria. Abnormal findings trigger treatment and further kidney evaluation. NCBI

11. Serum creatinine and eGFR
    Checks kidney function. Serial trends help spot early decline and guide blood pressure and UTI prevention strategies. ajkd.org

12. Urine culture
    Confirms infection when UTIs are suspected due to reflux or obstruction and guides antibiotics. NCBI

13. Targeted multigene genetic panel
    DNA testing of EYA1 and SIX1 (and, when indicated, related genes) using sequencing and copy-number analysis confirms the diagnosis in many families. Results also help with family counseling. NCBI

14. Chromosomal microarray or CNV analysis
    Detects small deletions/duplications that affect EYA1 or nearby regulatory regions when sequencing is negative. NCBI

15. Exome/genome sequencing
    Used when panel testing is negative but clinical suspicion remains high, as other rare loci may be involved. Nature

D) Electrodiagnostic & Physiologic Hearing Tests

16. Auditory Brainstem Response (ABR)
    An objective test that records brainstem responses to sound. It is useful in babies, young children, or when behavioral testing is hard. NCBI

17. Otoacoustic Emissions (OAE)
    Measures echoes from the inner ear’s outer hair cells. Absent OAEs suggest sensorineural loss. Often used in newborn screening and follow-up. NCBI

18. Comprehensive audiometry (pure-tone and speech testing)
    Determines degree (mild to profound) and type (conductive, sensorineural, mixed) of hearing loss to guide hearing aids, surgery, or implants. PubMed

E) Imaging Tests

19. Renal and urinary tract ultrasound
    A first-line, radiation-free test to detect small kidneys, hydronephrosis, duplex systems, and structural differences. It also helps monitor changes over time. NCBI

20. Voiding cystourethrogram (VCUG)
    An X-ray test with contrast that shows vesicoureteral reflux or urethral obstruction. It guides reflux management and UTI prevention. NCBI

21. Temporal bone CT
    Shows canal stenosis, ossicle differences, enlarged vestibular aqueduct, and other bony ear malformations that affect surgery planning. PubMed

22. Inner-ear MRI
    Shows the cochlea, vestibular system, nerves, and soft tissues. Helpful for cochlear implant planning or when CT findings are unclear. PubMed

Non-pharmacological treatments

1) Early newborn and childhood hearing screening.
Purpose: Find hearing loss quickly to protect speech and learning.
Mechanism: OAE/ABR tools detect inner ear or pathway problems even in sleeping babies; early detection opens the door to amplification, therapy, or cochlear implant when needed. NCBI

2) Hearing aids (air-conduction or bone-anchored).
Purpose: Improve access to sound and speech.
Mechanism: Devices amplify sound (air-conduction) or transmit vibration through bone when ear canals/ossicles are malformed, raising audibility and speech clarity. NCBI

3) Cochlear implant evaluation when hearing loss is severe.
Purpose: Restore access to sound when hearing aids are not enough.
Mechanism: An internal electrode stimulates the auditory nerve directly; external processor converts sound into coded signals. Benefit depends on cochlear/nerve anatomy and rehab. NCBI

4) Speech-language therapy and early intervention.
Purpose: Build listening, speech, and language.
Mechanism: Structured practice strengthens auditory processing and expressive skills; therapy works best when started early and paired with consistent device use. NCBI

5) Educational accommodations (FM/DM systems, seating, captions).
Purpose: Reduce classroom listening strain and improve learning.
Mechanism: Microphone systems send the teacher’s voice directly to the child’s device; captions and good seating improve signal-to-noise ratio. NCBI

6) ENT care for otitis media and canal problems.
Purpose: Prevent hearing dips from middle-ear fluid/infection.
Mechanism: Regular checks and timely procedures (e.g., tubes if appropriate) keep the middle ear clear and protect language development. NCBI

7) Water and ear-canal precautions.
Purpose: Lower infection risk when canals or eardrums are abnormal.
Mechanism: Custom plugs, avoiding cotton swabs, and safe drying reduce bacterial growth and trauma. rarediseases.org

8) Audiology follow-up across life.
Purpose: Track progression and update device settings.
Mechanism: Regular audiograms and device checks maintain best audibility as needs change. NCBI

9) Genetic counseling for families.
Purpose: Explain inheritance, testing options, and family planning.
Mechanism: Counselors review autosomal-dominant risk (about 50%), discuss targeted testing for relatives, and explain prenatal/preimplantation options. NCBI

10) Kidney-sparing lifestyle (BP, sodium, hydration).
Purpose: Slow kidney damage and protect heart health.
Mechanism: Low-sodium diet, home BP checks, exercise, and careful hydration reduce pressure and protein leak stresses on kidneys. NCBI

11) CKD dietitian support (protein, phosphorus, potassium).
Purpose: Keep minerals balanced and prevent bone disease.
Mechanism: Meal plans fit CKD stage; phosphorus and sometimes potassium are limited; adequate protein is balanced with kidney workload. NCBI

12) Avoid nephrotoxins and ototoxins.
Purpose: Prevent drug-related hearing or kidney injury.
Mechanism: Clinicians choose safer antibiotics and pain relievers when possible; patients avoid NSAID overuse and report any ringing, hearing change, or low urine output early. NCBI

13) UTI prevention routines.
Purpose: Reduce infections and scarring in refluxing systems.
Mechanism: Timed voiding, hydration, prompt culture-guided treatment, and voiding habit support lower UTI risk. NCBI

14) Blood-pressure monitoring at home.
Purpose: Catch early hypertension from kidney disease.
Mechanism: Regular readings guide visits and treatment adjustments to protect kidneys and the heart. NCBI

15) Vaccinations (including pneumococcal, flu).
Purpose: Lower infectious burden in children with ear/kidney issues.
Mechanism: Immunization reduces severe infections that can worsen hearing or kidney function. NCBI

16) Psychosocial support and peer groups.
Purpose: Address stress, learning needs, and family coping.
Mechanism: Counseling and support networks improve adherence, school success, and quality of life. rarediseases.org

17) Vestibular/balance therapy if dizzy.
Purpose: Improve balance and reduce falls.
Mechanism: Targeted exercises retrain gaze and balance pathways when inner-ear anatomy affects vestibular input. NCBI

18) Renal replacement education (when advanced CKD).
Purpose: Prepare for dialysis or transplant decisions.
Mechanism: Early teaching helps families choose peritoneal vs hemodialysis and plan for transplant evaluation in time. NCBI

19) Multidisciplinary clinic follow-up.
Purpose: Coordinate ENT, audiology, nephrology, genetics, and rehab.
Mechanism: Shared plans reduce missed problems and streamline surgeries or device upgrades. NCBI

20) Lifelong surveillance plan (ears, kidneys, BP).
Purpose: Protect hearing, speech, growth, and kidney health across life.
Mechanism: Yearly audiology/ENT checks, regular labs and ultrasound, and BP targets prevent silent decline. NCBI

---

Drug treatments

1) Lisinopril (ACE inhibitor).
Class & purpose: ACE inhibitor used for hypertension and proteinuric kidney disease to protect kidneys.
Dose/time: Adults often start 5–10 mg once daily and titrate; pediatric dosing exists.
Mechanism: Blocks angiotensin-converting enzyme, lowering angiotensin II, relaxing vessels, and reducing intraglomerular pressure, which can lower protein leak.
Side effects: Cough, high potassium, kidney function changes; boxed warning for fetal toxicity—stop if pregnant. Use and dosing must be individualized by a clinician. FDA Access Data+1

2) Losartan (ARB).
Class & purpose: Angiotensin receptor blocker for BP control and kidney protection when ACE inhibitors are not tolerated.
Dose/time: Common start 50 mg once daily; adjust with clinician guidance.
Mechanism: Blocks AT1 receptors, lowering vasoconstriction and filtration pressure.
Side effects: Dizziness, high potassium, low BP; avoid with aliskiren in diabetes; pregnancy warning similar to ACE inhibitors. FDA Access Data+1

3) Furosemide (loop diuretic).
Class & purpose: Diuretic for edema and BP control in renal disease.
Dose/time: Oral or IV; dose varies by weight, kidney function, and edema severity.
Mechanism: Blocks Na-K-2Cl transporter in the loop of Henle to remove salt and water.
Side effects: Low potassium, dehydration, dizziness, ototoxicity at high IV doses—use only under medical oversight. FDA Access Data+1

4) Ofloxacin otic 0.3%.
Class & purpose: Topical fluoroquinolone for otitis externa or chronic suppurative otitis media, commonly used when eardrum is perforated or tubes are present.
Dose/time: Drops into the ear as labeled; treatment days vary by indication.
Mechanism: Inhibits bacterial DNA gyrase, killing bacteria locally with minimal systemic exposure.
Side effects: Ear discomfort or taste disturbance; follow label technique. FDA Access Data+1

5) Amoxicillin–clavulanate.
Class & purpose: Broad beta-lactam/beta-lactamase inhibitor for otitis media or UTIs when organisms are susceptible.
Dose/time: Weight-based in children; adult doses vary by severity.
Mechanism: Amoxicillin blocks cell wall synthesis; clavulanate inhibits beta-lactamases.
Side effects: Diarrhea, rash; adjust dose in renal impairment. Use guided by cultures and clinician judgment. FDA Access Data

6) Ceftriaxone (parenteral).
Class & purpose: 3rd-generation cephalosporin for severe otitis media/UTI or pyelonephritis when IV therapy is needed.
Dose/time: IV/IM dosing per weight/indication.
Mechanism: Inhibits bacterial cell wall synthesis.
Side effects: Biliary sludging, diarrhea, allergy; dosing and duration are clinician-directed. FDA Access Data+1

7) Epoetin alfa.
Class & purpose: Erythropoiesis-stimulating agent (ESA) for anemia of CKD.
Dose/time: IV or subcutaneous; dosing is individualized to reach safe hemoglobin targets.
Mechanism: Stimulates red blood cell production.
Side effects: Hypertension, clot risk; ESAs carry boxed warnings—use only with close monitoring. FDA Access Data+1

8) Darbepoetin alfa.
Class & purpose: Longer-acting ESA for CKD anemia.
Dose/time: IV or subcutaneous at longer intervals than epoetin.
Mechanism: Same end effect—stimulates erythropoiesis.
Side effects: Similar ESA risks; careful dosing and targets are essential. FDA Access Data+1

9) Sevelamer carbonate (Renvela) / Sevelamer HCl (Renagel).
Class & purpose: Phosphate binders in CKD to control high serum phosphorus and protect bones/vessels.
Dose/time: With meals, titrated to phosphorus levels.
Mechanism: Non-absorbed polymer binds phosphate in the gut to reduce absorption.
Side effects: GI upset, constipation; avoid in bowel obstruction. FDA Access Data+2FDA Access Data+2

10) Calcitriol (oral or injectable).
Class & purpose: Active vitamin D for CKD-MBD (bone/mineral disorder) to manage hypocalcemia and PTH.
Dose/time: Microgram-level dosing, adjusted by labs.
Mechanism: Increases calcium absorption and suppresses PTH; overdose can cause hypercalcemia.
Side effects: High calcium and phosphate if overused—requires lab monitoring. FDA Access Data+1

11) Cinacalcet.
Class & purpose: Calcimimetic for secondary hyperparathyroidism in dialysis patients.
Dose/time: Oral; take with food; dose titrated to PTH and calcium.
Mechanism: Increases sensitivity of calcium-sensing receptor, lowering PTH.
Side effects: Hypocalcemia, GI effects; multiple drug interactions via CYP2D6. FDA Access Data+2FDA Access Data+2

12) Iron sucrose (Venofer).
Class & purpose: IV iron for CKD iron-deficiency anemia, especially with ESAs.
Dose/time: IV per protocol; pediatric dosing varies by CKD setting.
Mechanism: Replenishes iron for hemoglobin production.
Side effects: Hypersensitivity, hypotension; monitor during infusion. FDA Access Data+2FDA Access Data+2

13) Ofloxacin ophthalmic (for related ENT/eye care when needed).
Class & purpose: Eye antibiotic sometimes used if ENT-eye infections coexist; included because quinolone labeling clarifies safety profiles.
Dose/time: Per label for ophthalmic use.
Mechanism/side effects: Local antibacterial action; stinging, taste changes possible. FDA Access Data

14) Topical ear antibiotics per culture (class placeholder—label-guided).
Purpose: Culture-guided ear drops reduce infection burden in abnormal canals or with tubes.
Mechanism: High local antibiotic levels with limited systemic exposure; follow specific product labeling.
Side effects: Local irritation; rare hypersensitivity. FDA Access Data

15) Antihypertensive add-ons (e.g., thiazides) when needed.
Purpose: Reach BP goals if ACE/ARB alone is not enough.
Mechanism: Promote natriuresis and lower BP; selection depends on kidney function and potassium.
Side effects: Electrolyte shifts; clinician-guided. (Representative labeling referenced under ACE/ARB context.) FDA Access Data

16) Antibiotics for UTIs (culture-directed; e.g., amoxicillin–clavulanate).
Purpose: Clear infection quickly to prevent scarring.
Mechanism: Bactericidal action based on organism; dosing adjusted for kidney function.
Side effects: GI upset, allergy; use only when indicated by clinicians. FDA Access Data

17) Parenteral ceftriaxone for febrile UTI/pyelonephritis.
Purpose: Rapid control of severe infection.
Mechanism: Bactericidal cell wall inhibition.
Side effects: As above; hospital-guided care. FDA Access Data

18) ESA support combined with IV iron (protocol-based).
Purpose: Improve ESA response and reduce dose needs.
Mechanism: Iron availability plus erythropoietin stimulation builds hemoglobin safely.
Side effects: As above; careful lab-targeting is key. FDA Access Data+1

19) Loop diuretic optimization in edema crises.
Purpose: Symptom relief from volume overload.
Mechanism: Enhanced sodium-water excretion; may need combination strategies.
Side effects: Electrolyte loss; hearing risk at high IV rates. FDA Access Data

20) Individualized polypharmacy review to avoid ototoxic/nephrotoxic drugs.
Purpose: Safety in a high-risk ear/kidney setting.
Mechanism: Medication reconciliation removes risks (e.g., certain aminoglycosides or NSAIDs) and aligns with label cautions.
Side effects: Fewer adverse events with careful selection. NCBI

Important: Drug choices, doses, and durations must be set by your clinician for your situation, cultures, age, and kidney function. Labels above are FDA sources for general reference and do not replace medical advice.

---

Dietary molecular supplements

1) Vitamin D (cholecalciferol).
Dose: Often 600–1,000 IU/day in children/adults; CKD patients need clinician-guided dosing based on 25-OH D and calcium/phosphate.
Function/mechanism: Supports bone and mineral balance; improves calcium absorption; in CKD, active vitamin D analogs may still be needed. Avoid excess to prevent hypercalcemia. Office of Dietary Supplements

2) Omega-3 fatty acids (EPA/DHA).
Dose: Common supplements provide 1 g/day; clinicians may use higher under supervision.
Function/mechanism: Anti-inflammatory lipid mediators that can support cardiovascular health in CKD populations; food-first (fish) is preferred when possible. Monitor with anticoagulants. Office of Dietary Supplements

3) Magnesium (only if low and if safe in CKD).
Dose: Varies by product; CKD often requires caution or avoidance—use only if a clinician confirms deficiency and safety.
Function/mechanism: Cofactor in nerve, muscle, and heart function; deficiency can worsen cramps or arrhythmias. Office of Dietary Supplements

4) Folate (B9).
Dose: 400 mcg/day is common in adults; higher therapeutic doses only under care.
Function/mechanism: DNA synthesis and red-blood-cell production; helps reduce some anemia types when folate-deficient. Office of Dietary Supplements

5) Coenzyme Q10.
Dose: Many products 100–200 mg/day; quality varies.
Function/mechanism: Mitochondrial electron transport and antioxidant effects; studied for heart and fatigue; evidence mixed; generally safe but discuss with your clinician. NCBI+1

6) Iron (oral or IV per labs).
Dose: Oral iron varies; IV iron follows strict protocols.
Function/mechanism: Restores iron for hemoglobin and energy; in CKD, IV iron often works better with ESAs. Do not self-supplement iron without labs. (IV iron label under Drugs above.) FDA Access Data

7) Protein optimization (medical nutrition therapy).
Dose: Grams/kg/day tailored to age and CKD stage by a dietitian.
Function/mechanism: Enough protein for growth and repair while limiting kidney workload; balances nitrogen waste and muscle needs. NCBI

8) Calcium (only if indicated).
Dose: Individualized; excessive calcium can raise calcification risk in CKD.
Function/mechanism: Bone mineral support; combined with vitamin D when appropriate; CKD patients often need non-calcium binders instead. Office of Dietary Supplements

9) Probiotics (adjunct for gut health).
Dose: Varies by product; choose clinically studied strains.
Function/mechanism: May support gut barrier and reduce infection risk around antibiotic courses; evidence is evolving. Use with clinician advice. NCBI

10) Antioxidant-rich foods instead of pills.
Dose: Daily fruits/vegetables within potassium limits (CKD).
Function/mechanism: Whole-food antioxidants and fiber support vascular health and the microbiome without the risks of high-dose single-nutrient supplements. NCBI

---

Immunity-supporting / regenerative / stem-cell-related drugs

1) Epoetin alfa (ESA).
Dose: IV/SC; individualized by hemoglobin and iron.
Function/mechanism: Stimulates bone-marrow red-cell production, improving oxygen delivery when CKD anemia develops. Monitor BP and clot risk closely. FDA Access Data

2) Darbepoetin alfa (ESA).
Dose: Longer-acting dosing schedule than epoetin.
Function/mechanism: Same pathway; helps maintain stable hemoglobin with fewer injections; same boxed warnings and monitoring needs. FDA Access Data

3) Calcitriol (active vitamin D).
Dose: Microgram doses; titrate by PTH, Ca, P.
Function/mechanism: Modulates immune and bone signaling; reduces secondary hyperparathyroidism; overdose can cause hypercalcemia. FDA Access Data

4) Cinacalcet (calcimimetic).
Dose: Oral; titrate with labs.
Function/mechanism: Lowers PTH by sensitizing the calcium-sensing receptor; may indirectly improve bone turnover and mineral balance. FDA Access Data

5) Iron sucrose (IV).
Dose: Protocol-based IV infusions.
Function/mechanism: Restores iron stores for erythropoiesis, supporting immune competence tied to anemia correction. Monitor for reactions. FDA Access Data

6) (Context note) Stem-cell therapy is not standard for BOR itself.
Function/mechanism: No approved stem-cell drug corrects the gene defects in BOR; kidney transplantation remains the definitive “regenerative” option when kidneys fail. Use of experimental cell therapies should occur only in clinical trials. NCBI

---

Surgeries (what they are and why done)

Branchial cyst/fistula excision.
Surgeons remove the cyst or the whole tract to stop recurrent infections or drainage. This also confirms the diagnosis. Imaging helps map the tract before surgery. NCBI

Tympanostomy tubes (if recurrent otitis media with effusion).
Small ear tubes drain fluid and reduce infections, protecting hearing and language while the Eustachian tube matures. NCBI

Ossiculoplasty or canalplasty (selected cases).
In conductive loss from ossicle or canal malformation, reconstructive ear surgery can improve sound conduction when anatomy allows. NCBI

Cochlear implantation.
For severe to profound sensorineural loss, a cochlear implant bypasses damaged sensory cells and directly stimulates the nerve. It needs careful imaging and rehab for best outcomes. NCBI

Urologic/renal surgeries (e.g., ureteral reimplantation; transplant).
When reflux or obstruction is severe, urologic repair protects kidneys. In end-stage kidney disease, transplantation restores function and quality of life. NCBI

---

Preventions

1. Newborn hearing screening and fast follow-up. NCBI

2. Regular audiology and ENT checks. NCBI

3. Kidney ultrasound and labs on a schedule. NCBI

4. Prompt, culture-guided UTI care. NCBI

5. Blood-pressure control with home monitoring. NCBI

6. Low-sodium and kidney-friendly diet. NCBI

7. Avoid ototoxic and nephrotoxic medicines when possible. NCBI

8. Vaccinations (flu, pneumococcus as advised). NCBI

9. Noise protection for hearing conservation. NCBI

10. Genetic counseling for family planning and early testing of at-risk relatives. NCBI

---

When to see doctors (red flags)

See a doctor right away for ear pain with fever, ear drainage, sudden hearing drop, new neck swelling/redness, painful urination or fever, swelling of legs or face, very high blood pressure numbers, very low urine output, severe dizziness, or any fast change in a child’s speech and listening. Families with known BOR should keep regular visits with ENT, audiology, nephrology, and genetics even when feeling well, because hearing and kidney problems can progress silently. NCBI

---

Foods to favor and to limit/avoid

What to eat (examples):

1. Fresh herbs/spices instead of salt,

2. whole grains in proper portions,

3. lean proteins (fish, chicken) adjusted to CKD stage,

4. low-potassium fruits (apples, berries) if potassium runs high,

5. low-phosphorus vegetables (green beans, cabbage) as advised,

6. olive or canola oil,

7. yogurt/milk substitutes chosen for low phosphorus content if needed,

8. water in amounts set by your team,

9. fiber-rich foods for gut health,

10. foods rich in natural antioxidants within mineral limits. NCBI

What to limit/avoid (examples):

1. High-sodium packaged foods,

2. processed meats,

3. very salty snacks,

4. dark colas (phosphorus),

5. high-phosphorus additives,

6. very high-potassium items when potassium is high (e.g., large servings of bananas, oranges),

7. excess red meat,

8. herbal supplements without clinician review,

9. large doses of vitamin D, calcium, or magnesium without labs,

10. NSAID overuse. A renal dietitian personalizes this list. NCBI

---

Frequently asked questions

1) Is Melnick–Fraser the same as BOR?
Yes. Melnick–Fraser is another name for BOR spectrum disorder. Iowa Head and Neck Protocols

2) Can you have ear and neck findings without kidney disease?
Yes; that is often called branchio-otic (BO) syndrome. MedlinePlus

3) What genes are most often involved?
EYA1 most often; SIX1 and SIX5 are less common. NCBI+1

4) How is it inherited?
Autosomal dominant; each child of an affected parent has about a 50% chance. NCBI

5) How common is it?
Rare; estimates near 1 in 40,000 in some countries. onlinelibrary.wiley.com

6) When should a child be tested?
Early—after screening finds hearing loss or when physical signs (pits, cysts) are present; genetics helps confirm and guide screening for kidneys. NCBI

7) Can hearing get worse over time?
Yes; progression can happen, so regular audiology checks are needed. NCBI

8) What kidney checks are needed?
Labs (creatinine/eGFR, urine), blood pressure, and ultrasound; more tests if reflux or scarring is suspected. NCBI

9) Are there medicines that change the genes?
No. Care targets the hearing and kidney complications and prevents damage. NCBI

10) Do ACE inhibitors or ARBs help?
They help control BP and protein leak, which may slow damage in proteinuric kidney disease. FDA Access Data+1

11) Are ear drops safe with a perforation or tubes?
Some labeled drops (e.g., ofloxacin otic) are used specifically in these settings—follow clinician guidance. FDA Access Data

12) What about anemia in CKD?
ESAs (epoetin/darbepoetin) and iron are used under strict lab monitoring. FDA Access Data+2FDA Access Data+2

13) Should we change diet?
Yes—low sodium, balanced protein, and mineral management by a renal dietitian; details depend on CKD stage and labs. NCBI

14) Is pregnancy risk different?
There’s a 50% inheritance risk; ACEi/ARBs must be stopped if pregnant; genetic counseling helps with planning. FDA Access Data+1

15) Is transplant a cure for the kidney part?
Transplant replaces kidney function; hearing/neck findings still need ENT/audiology care. NCBI

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: November 02, 2025.